Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

0.8066 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Analysts Still Believe Verrica's Ycanth Is Approvable Despite FDA Response Letter
Via Benzinga
Verrica Holds Type A Meeting With FDA For Potential Approval Of Skin Infection Candidate
The U.S. Food and Drug Administration (FDA) convened a Type A meeting with Verrica Pharmaceuticals (NASDAQ: VRCA) regarding the course of action for the clearance of its drug candidate VP-102. 
Via Benzinga
Verrica Pharmaceuticals Inc. Investor News: Robbins LLP is Investigating Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
Analyst Ratings for Verrica Pharmaceuticals
Within the last quarter, Verrica Pharmaceuticals (NASDAQ:VRCA) has observed the following analyst ratings: 
Via Benzinga
NASDAQ:VRCA Investor Notice: Lawsuit Alleges Misleading Statements by Verrica Pharmaceuticals Inc.
San Diego, CA -- (SBWIRE) -- 06/21/2022 -- An investor, who purchased NASDAQ:VRCA shares, filed a lawsuit against Verrica Pharmaceuticals Inc over alleged violations of Federal Securities Laws. 
Via SBWire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Verrica Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VRCA
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Verrica Pharmaceuticals, Inc. (VRCA) Investors and Encourages Investors to Contact the Firm Before August 5, 2022
From Kirby McInerney LLP
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers 
Via Benzinga
VRCA Investor Update: Robbins LLP Reminds Investors of Class Action Against Verrica Pharmaceuticals Inc. (VRCA)
From Robbins LLP
Via Business Wire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)
From Glancy Prongay & Murray LLP
Via Business Wire
Stockholder Alert: Robbins LLP Informs Investors of Class Action Against Verrica Pharmacuticals Inc. (VRCA)
From Robbins LLP
Via Business Wire
VRCA Stockholder News: Robbins LLP Investigates Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Stockholders
From Robbins LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)
From Law Offices of Howard G. Smith
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Verrica Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – VRCA
From The Rosen Law Firm, P.A.
Via Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals, Inc. (VRCA) Investors
From Kirby McInerney LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals Inc. (VRCA) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Verrica Pharmaceuticals Inc. (VRCA) Investors of Class Action and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
VERRICA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verrica Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
VRCA CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc.
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals Inc. (VRCA) Investors
From Law Offices of Howard G. Smith
Via Business Wire
VRCA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Verrica Pharmaceuticals Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
NASDAQ:VRCA Shareholder Notice: Investigation over Potential Securities Laws Violations by Verrica Pharmaceuticals Inc.
San Diego, CA -- (SBWIRE) -- 06/06/2022 -- Verrica Pharmaceuticals Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Verrica Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback